NanoViricides celebrates grand opening of new facility

NanoViricides, Inc., a developmental-stage biopharmaceutical company, celebrated the grand opening on Monday of its new research and development and current good manufacturing practices pilot manufacturing facility.

The company, which is developing drugs against viral diseases like H1N1 swine flu, H5N1 bird flu and Ebola virus, welcomed delegates to the West Haven, Conn.-based facility from Sens. Chris Murphy (D-Conn.) and Richard Blumenthal (D-Conn.) and Conn. Gov. Dannel Malloy. Anil Diwan, the president and chairman of NanoViricides, led the dignitaries on a tour of the facility and spoke about the potential of the company's nanoviricides technology to create effective drugs against viral diseases, according to a company press release.

"This day brings with it the promise of high-skill jobs creation here in Connecticut, the advancement of truly groundbreaking medical technologies, and a continuation of international respect that (NanoViricides) has commanded since its founding," Murphy said.

Eugene Seymour, the CEO of NanoViricides, compared the high levels of effectiveness observed for the company's drug candidates with the dramatic effectiveness that penicillin demonstrated in the first U.S. patient treated with the drug in 1942. He said the nanoviricides technology could be as transformative against viral diseases as penicillin had been against bacterial diseases.

NanoViricides develops special purpose nanomaterials for antiviral therapy that attack enveloped virus particles and dismantle them.